ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

Table 1 The sequences of primers and probes

Primers or probes	Sequences (5'-3')	Length ofproduct (bp)
actin-U	AGAAGATGACCCAGATCATGTT	290
actin-L	CTTAATGTCACGCACGATTTCC
ERCC1-U	TACCACAACCTGCACCCAGACTAC	321
ERCC1-L	CTGACTGTCCGTTTTGTTGACTGA
ERCC1-118-U	GGTCATCCCTATTGATGGCTTCTG	154
ERCC1-118-L	AGCTCACCTGAGGAACAGGGCACAG
ERCC1-118-P	p-TTGCGCACGAACTTCAGTACGGGAT
	GGGACACTAATCGGAGGATTA-FAM
ERCC1-118-T	CTACGGAG GATTATGAGGAGCTGCGT	92
	CGCCAAATTCCCAGGGCACA
ERCC1-118-C	CTACGAAATCAGGAGGATTATGAGGA	97
	GACGTCGCCAAATTCCCAGGG CACG

Table 2 Relationship among ERCC1 genotypes, mRNA expression and clinical characteristics of gastric cancer

Clinical characteristics	n	ERCC1 polymorphism		χ2	P	ERCC1 mRNA		χ2	P
		C/C (n = 45)	C/T + T/T (n = 44)			High value (n = 31)	Low value (n = 31)
Age (yr)
≥ 58	48	25	23	0.096	0.833	18	18	0	1.000
< 58	41	20	21			13	13
Gender
Male	66	31	35	1.318	0.334	20	24	0.253	0.402
Female	23	14	9			11	7
TNM stage
I-II	19	13	6	3.082	0.079	6	6	0	1.000
III-IV	70	31	39			25	25
Grading
G2	45	20	24	0.552	0.527	15	19	1.042	0.444
G3	44	21	20			16	12